ReviewESMO gastrointestinal oncology2026
Assessing the relationship between event-free and overall survival in randomized controlled trials of perioperative chemoimmunotherapy in gastroesophageal cancers.
Review in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perioperative chemoimmunotherapy is emerging as a global standard for nonmetastatic gastroesophageal cancers. Event-free survival (EFS) is a common endpoint in perioperative trials; however, its validity as a surrogate for overall survival (OS) in randomized controlled trials in the era of chemoimmunotherapy is not well established. Materials and methods: We carried out a systematic review to identify randomized controlled trials evaluating neoadjuvant or perioperative therapy for gastroesophageal adenocarcinomas. Weighted linear regression of the published hazard ratios (HRs) was used to evaluate the correlation between EFS and OS. Criteria from the Institute for Quality and Efficiency in Health Care defined surrogacy strength. Sensitivity analyses evaluating heterogeneous tumor locations, perioperative systemic therapy only, and trials with clearly defined EFS were carried out. Results: Thirty trials comprising 11 453 participants were included in the main analysis. Trial-level analysis identified a positive relationship between EFS and OS ( Conclusions: EFS is a valid surrogate for OS at the trial level in randomized controlled perioperative trials in modern nonmetastatic gastroesophageal trials, supporting the validity of intermediate endpoints for use in development of novel treatment strategies and regulatory considerations in gastroesophageal adenocarcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.